Humacyte, Inc.

As of June 30, 2026, Humacyte, Inc. carries a market capitalization of 216.79M, placing it among publicly traded companies globally. Its enterprise value stands at 203.07M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Humacyte, Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Humacyte, Inc. has 277.80M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 71.48, and the price-to-book ratio stands at 6.93.

These figures are as of June 30, 2026. The EV/Sales ratio of 95.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 203.07M versus a market cap of 216.79M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Humacyte, Inc. maintains a current ratio of 6.21, meaning it holds 6.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 211.70, indicating elevated leverage, while an interest coverage ratio of -10.09 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Humacyte, Inc. posted a negative return on equity (ROE) of -547.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -69.87, reflecting losses generated across the asset base. The company generates approximately 10,989.64 in revenue per employee across its workforce of 193.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.40 indicates how many times Humacyte, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Humacyte, Inc.'s stock has declined approximately 74.50% over the past 52 weeks. The 50-day moving average sits at 0.55, while the 200-day moving average is 0.83.

Over the twelve months ended June 30, 2026, Humacyte, Inc. generated 2.12M in revenue and converted that into -96.73M in net income, yielding earnings per share of -0.50. EBITDA reached -103.93M, while operating income came in at -111.16M.

As of June 30, 2026, Humacyte, Inc. holds 79.90M in cash and equivalents against 66.18M in total debt, resulting in a net debt position of -43.58M. Total book value stands at 31.26M, with working capital of 77.84M providing operational flexibility.

Humacyte, Inc. produced -97.19M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -367,000.00 in capital expenditures, free cash flow totaled -97.56M - equivalent to -0.50 per share.

Over the twelve months ended June 30, 2026, Humacyte, Inc. posted a gross margin of -494.58, reflecting its pricing power and cost economics. The operating margin of -5,240.78 and net profit margin of -4,560.82 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Humacyte, Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -64.35: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -41.25, meaning Humacyte, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Humacyte, Inc. has an Altman Z-Score of -8.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.